Artificial Intelligence (AI) Pathology Quality Control Market Forecast 2026–2030: Market Size, Trends And Growth Opportunities
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Artificial Intelligence (AI) Pathology Quality Control Market Growth From $2.16 Billion In 2026 To $4.65 Billion By 2030 At A CAGR Of 21.1%
The artificial intelligence (AI) pathology quality control market size has experienced significant expansion in recent years. Its valuation is predicted to climb from $1.78 billion in 2025 to $2.16 billion in 2026, registering a compound annual growth rate (CAGR) of 21.4%. This past growth can be ascribed to a number of elements, such as increasing pathology workload volumes, the initial digitization of pathology slides, the growing complexity of cancer diagnostics, the demand for standardized reporting, and the early adoption of AI-assisted pathology tools.
The artificial intelligence (AI) pathology quality control market is set for substantial growth in the upcoming years. It is projected to expand to $4.65 billion by 2030, achieving a compound annual growth rate (CAGR) of 21.1%. This growth during the forecast period is driven by increasing investments in digital pathology platforms, a heightened demand for precision diagnostics, the expanding validation of AI within clinical workflows, the rising integration of pathology data analytics, and a greater regulatory emphasis on diagnostic quality control. Significant trends expected in this period include the wider deployment of AI-based slide quality assessment, the increasing adoption of automated error detection tools, the growing standardization of pathology workflows, the broadened integration of digital pathology, and an enhanced focus on ensuring diagnostic accuracy.
Get A Free Sample Report With In-Depth Market Insights:
Artificial Intelligence (AI) Pathology Quality Control Market Growth Backed By Core Demand Fundamentals
The burgeoning need for personalized medicine is anticipated to fuel the expansion of the artificial intelligence (AI) pathology quality control market in the future. Personalized medicine is defined as a healthcare method that customizes treatment and prevention plans based on an individual’s distinct genetic profile, way of life, and surroundings. The growing acceptance of personalized medicine is largely driven by progress in genomics, allowing for accurate detection of genetic differences and bespoke therapies for patients. Artificial intelligence (AI) pathology quality control improves personalized medicine through providing accurate and uniform diagnostic information, thereby supporting customized treatment approaches. This technology mitigates diagnostic mistakes by automating quality verification, boosting precision and dependability, and ultimately furthering care specific to each patient. For example, in February 2024, data from the Personalized Medicine Coalition (PMC), a US-based nonprofit, revealed that the U.S. Food and Drug Administration (FDA) gave its approval to 26 new personalized medicines in 2023, marking a substantial rise from the 12 approved in 2022. Consequently, the rising demand for personalized medicine is set to propel the artificial intelligence (AI) pathology quality control market.
Artificial Intelligence (AI) Pathology Quality Control Market Segment Trends And Revenue Contributors
The artificial intelligence (AI) pathology quality control market covered in this report is segmented –
1) By Component: Software, Hardware, Services
2) By Deployment Mode: On-Premises, Cloud-Based
3) By Application: Cancer Diagnostics, Infectious Disease Diagnostics, Digital Pathology, Research, Other Applications
4) By End-User: Hospitals, Diagnostic Laboratories, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users
Subsegments:
1) By Software: Image Analysis Software, Diagnostic Decision Support Software, Workflow Management Software, Reporting And Visualization Software
2) By Hardware: Digital Pathology Scanners, Imaging Devices, Servers And Storage Systems, Laboratory Equipment
3) By Services: Implementation Services, Training And Support Services, Maintenance And Upgrade Services, Consulting Services
Artificial Intelligence (AI) Pathology Quality Control Market Growth Trends Reshaping The Competitive Landscape
Leading companies in the artificial intelligence (AI) pathology quality control market are concentrating on developing advanced solutions, such as sophisticated AI-powered tools, aimed at improving diagnostic accuracy, streamlining laboratory workflows, and ensuring the reliability of pathology data. These advanced AI-powered solutions are next-generation technologies that utilize artificial intelligence to execute complex tasks with increased accuracy, speed, and efficiency. For example, in November 2023, PathAI, a US-based biotechnology company, unveiled Artifact Detect 1 on its AISight digital pathology platform. This tool automates the identification and quantification of artifacts in whole slide images (WSI), which are non-relevant morphological features that can compromise diagnostic accuracy. ArtifactDetect helps minimize misdiagnosis and the need for re-scans by automatically pre-screening slides for quality issues, thereby enhancing accuracy, laboratory efficiency, and overall throughput. This innovation supports timely corrective actions like re-staining or re-scanning, ultimately refining the digital workflow and conserving resources for technicians and pathologists.
Artificial Intelligence (AI) Pathology Quality Control Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the artificial intelligence (AI) pathology quality control market are Roche Diagnostics GmbH, Danaher Corporation, Philips Healthcare, Agilent Technologies Inc., Hologic Inc., Clinisys Group Ltd., Sectra AB, PathAI Inc., OptraSCAN Inc., Paige.AI Inc., Proscia Inc., Quibim S.L., 3DHISTECH Ltd., Visiopharm A/S, Indica Labs Inc., Ibex Medical Analytics Ltd., Aiosyn B.V., DeepBio Inc., Nucleai Ltd., Gestalt Diagnostics LLC
View The Full Artificial Intelligence (AI) Pathology Quality Control Market Report:
Artificial Intelligence (AI) Pathology Quality Control Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the artificial intelligence (AI) pathology quality control market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) pathology quality control market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
